AbbVie Inc. Files 8-K on Financials and Debt
Ticker: ABBV · Form: 8-K · Filed: Jan 31, 2025 · CIK: 1551152
| Field | Detail |
|---|---|
| Company | Abbvie Inc. (ABBV) |
| Form Type | 8-K |
| Filed Date | Jan 31, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, debt, filing
Related Tickers: ABBV
TL;DR
AbbVie dropped its 8-K on Jan 31, 2025 - check out the debt details!
AI Summary
On January 31, 2025, AbbVie Inc. filed an 8-K report detailing its financial condition and results of operations. The filing includes information on various senior notes, such as the Sec0.750 Senior Notes Due 2027 and Sec2.125 Senior Notes Due 2028, indicating ongoing financial activities and debt management.
Why It Matters
This filing provides investors with crucial updates on AbbVie's financial health and its outstanding debt instruments, impacting investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant risks.
Key Players & Entities
- AbbVie Inc. (company) — Filer of the 8-K report
- January 31, 2025 (date) — Date of the earliest event reported
- Sec0.750 Senior Notes Due 2027 (dollar_amount) — Specific debt instrument mentioned
- Sec2.125 Senior Notes Due 2028 (dollar_amount) — Specific debt instrument mentioned
FAQ
What is the primary purpose of this 8-K filing by AbbVie Inc.?
The primary purpose of this 8-K filing is to report on AbbVie Inc.'s results of operations and financial condition, as well as to include financial statements and exhibits.
What is the filing date for this 8-K report?
The 8-K report was filed as of January 31, 2025.
Which specific senior notes are mentioned in the filing details?
The filing details mention several senior notes, including Sec0.750 Senior Notes Due 2027, Sec2.125 Senior Notes Due 2028, Sec2625 Senior Notes Due 2028, Sec2125 Senior Notes Due 2029, and Sec1250 Senior Notes Due 2031.
What is AbbVie Inc.'s Standard Industrial Classification (SIC) code?
AbbVie Inc.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Where is AbbVie Inc. headquartered?
AbbVie Inc. is headquartered in North Chicago, Illinois, with its business and mail address listed as 1 North Waukegan Road, North Chicago, IL 60064.
Filing Stats: 487 words · 2 min read · ~2 pages · Grade level 9.3 · Accepted 2025-01-31 07:42:37
Key Financial Figures
- $0.01 — ange on which registered Common Stock, $0.01 Par Value ABBV New York Stock Exchange
Filing Documents
- abbv-20250131.htm (8-K) — 39KB
- abbv-20241231xexhibit991.htm (EX-99.1) — 494KB
- abbvieimage1a53.jpg (GRAPHIC) — 15KB
- 0001551152-25-000011.txt ( ) — 787KB
- abbv-20250131.xsd (EX-101.SCH) — 4KB
- abbv-20250131_def.xml (EX-101.DEF) — 19KB
- abbv-20250131_lab.xml (EX-101.LAB) — 35KB
- abbv-20250131_pre.xml (EX-101.PRE) — 20KB
- abbv-20250131_htm.xml (XML) — 8KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition On January 31, 2025, AbbVie Inc. issued a press release announcing financial results for the fourth quarter and full year ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Exhibit 99.1 Press Release dated Janu ary 31 , 202 5 (furnished pursuant to Item 2.02). 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABBVIE INC. Date: January 31, 2025 By: /s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer